enGene Holdings Inc ENGN

NAS: ENGN | ISIN: CA29286M1059 22:00

15,32 USD (-3,59%)

(-3,59%) 22:00

Grafiek enGene Holdings Inc

Grafiek enGene Holdings Inc

1 dag1d -3,59%
1 week1w 4,08%
1 maand1m -9,35%
3 maanden3m 97,68%
6 maanden6m -19,37%
1 jaar1j -23,40%
5 jaar5j -23,40%

enGene Holdings Inc in het nieuws

Toon enkel gratis nieuws

2 mei 2024 · enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual Meeting · Persbericht

9 april 2024 · /C O R R E C T I O N -- enGene Inc./ · Persbericht

9 april 2024 · enGene Announces Hiring of Dr. Raj Pruthi as Senior Vice President, Urologic Oncology and Clinical Development · Persbericht

9 april 2024 · enGene Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development · Persbericht

9 april 2024 · engender Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development · Persbericht

11 maart 2024 · enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress · Persbericht

5 maart 2024 · enGene To Present at the Leerink Partners Global Biopharma Conference · Persbericht

14 februari 2024 · enGene Announces Oversubscribed $200 Million Private Placement Financing · Persbericht

14 februari 2024 · enGene Announces Leadership Succession Plan · Persbericht

30 januari 2024 · enGene Appoints Lee Giguere as Chief Legal Officer and Corporate Secretary · Persbericht

Aandelen enGene Holdings Inc

Beurswaarde: 692,51 miljoen USD

Effecten: 43,58 miljoen

Beta: -0,11

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe